Novavax | NVAX - Current Assets


Novavax reported $707.96M in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Adma Biologics USD 575.86M 47.66M Sep/2026
Agenus USD 78.81M 16.47M Jun/2026
AstraZeneca USD 31.45B 3.48B Sep/2026
BioCryst Pharmaceuticals USD 531.15M 46.47M Sep/2026
Cassava Sciences USD 80.06M 3.67M Sep/2026
Geron USD 468.74M 17.6M Sep/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
MannKind USD 240.48M 5.24M Sep/2026
Merck USD 38.94B 2.26B Sep/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Moderna USD 5.82B 45M Jun/2026
Novartis USD 28.75B 2.14B Sep/2026
Novavax USD 707.96M 63.14M Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Sanofi EUR 33.21B 1.68B Sep/2026
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
TG Therapeutics USD 1.15B 58.72M Jun/2026